Epcore Fl 1 Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lorenzo Falchi, MD, discusses the ongoing EPCORE FL-1 phase 3 trial investigating epcoritamab-rituximab-lenalidomide vs rituximab-lenalidomide in patients with relapsed or refractory follicular lymphoma.

United statesSan diegoLorenzo falchiDrug administrationEastern cooperative oncology groupSubcutaneous epcoritamab with rituximabPatients with relapsedRefractory follicularPartnership withNorth americaSouth americaSubcutaneous epcoritamabEpcore fl 1Follicular lymphomaRelapsed refractory follicular lymphomaEpcore fl 1 trial